Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | DPP4 | P27487 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
| ▸ | HRH2 | P25021 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | KDM2B | Q8NHM5 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28322872 | 0.84 | KMT2A (0.47) | NPC1RAB9ADPP4ALDH1A1GAA | |
| SCHEMBL28321868 | 0.84 | KMT2A (0.47) | NPC1RAB9ADPP4ALDH1A1GAA | |
| SCHEMBL10903756 | 0.82 | DPP4 (0.47) | NPC1RAB9AMAPK1DPP4ALDH1A1 | |
| SCHEMBL28322880 | 0.82 | MEN1 (0.54) | NPC1RAB9AALDH1A1KMT2APOLB | |
| SCHEMBL27623273 | 0.80 | ELANE (0.43) | KMT2AHRH2HRH1CA1CA2 | |
| SCHEMBL29131652 | 0.79 | ELANE (0.40) | DPP4HRH2HRH1 | |
| SCHEMBL18589371 | 0.79 | MGLL (0.44) | ALDH1A1CES2CES1KDM2B | |
| SCHEMBL18607990 | 0.79 | MGLL (0.44) | ALDH1A1CES2CES1KDM2B | |
| SCHEMBL7416214 | 0.79 | HSD11B1 (0.44) | NPC1RAB9AALDH1A1POLBCES2 | |
| SCHEMBL12361339 | 0.79 | MGLL (0.44) | ALDH1A1CES2CES1KDM2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112574235-B | RET inhibitor, pharmaceutical composition and application thereof | 广东东阳光药业股份有限公司 | 2024-01-16 | — | — | CN | disclosed |
| EP-3601232-B1 | COMPOSITIONS AND METHODS COMPRISING SUBSTITUTED 2-AMINOIMIDAZOLES | CURZA GLOBAL LLC (US) | 2022-11-23 | — | — | EP | disclosed |
| US-20220274949-A1 | COMPOSITIONS AND METHODS COMPRISING SUBSTITUTED 2-AMINOIMIDAZOLES | CURZA GLOBAL, LLC (US) | 2022-09-01 | — | — | US | disclosed |
| US-11339140-B2 | Compositions and methods comprising substituted 2-aminoimidazoles | CURZA GLOBAL, LLC (US) | 2022-05-24 | — | — | US | disclosed |
| US-11339140-B2 | Compositions and methods comprising substituted 2-aminoimidazoles | CURZA GLOBAL, LLC (US) | 2022-05-24 | — | — | US | disclosed |
| CN-112574236-A | RET inhibitor, pharmaceutical composition and application thereof | 广东东阳光药业有限公司 | 2021-03-30 | — | — | CN | disclosed |
| CN-112574235-A | RET inhibitor, pharmaceutical composition and application thereof | 广东东阳光药业有限公司 | 2021-03-30 | — | — | CN | disclosed |
| CN-112442050-A | RET inhibitor, pharmaceutical composition and application thereof | 广东东阳光药业有限公司 | 2021-03-05 | — | — | CN | disclosed |
| EP-3601232-A1 | COMPOSITIONS AND METHODS COMPRISING SUBSTITUTED 2-AMINOIMIDAZOLES | Curza Global LLC (US) | 2020-02-05 | — | — | EP | disclosed |
| WO-2018184019-A1 | COMPOSITIONS AND METHODS COMPRISING SUBSTITUTED 2-AMINOIMIDAZOLES | CURZA GLOBAL, LLC (US) | 2018-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220274949-A1 | COMPOSITIONS AND METHODS COMPRISING SUBSTITUTED 2-AMINOIMIDAZOLES | AADAC, PAICS, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | NPC1 2167/4885RAB9A 2436/4885MAPK1 4497/4885 |
| US-11339140-B2 | Compositions and methods comprising substituted 2-aminoimidazoles | AADAC, PAICS, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | NPC1 2167/4885RAB9A 2436/4885MAPK1 4497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.